ANI Pharmaceuticals submits supplemental application for Oxycodone and Aspirin
ANI Pharmaceuticals has submitted a supplemental application for a combination product containing Oxycodone and Aspirin.
Asset / Drug
Drug and asset intelligence for ANI with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.